|Description||A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).|
|Brife Description||A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities.|
|Sequence||Light Chain Sequence:
Heavy Chain Sequence:
|Synonyms||Atezolizumab; RG-7446; RO 5541267; TECENTRIQ|
|Current Developer||Chugai Pharmaceutical; Clovis Oncology; Columbia University; Genentech; Immune Design; Incyte Corporation; M. D. Anderson Cancer Center; Roche; University Medical Center Groningen; University of California at San Francisco; University of California System; Yale University|
A first-in-class oral, small molecule antagonist of PD-L1, PD-L2 and V-region immunoglobulin-containing suppressor of T cell activation (VISTA).
PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1).
Anti-PD-L1 monoclonal antibody BMS-936559 binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance th...
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody. It was approved by FDA for the treatment of patients with locally advanced or metasta...
Avelumab is a human monoclonal antibody that is commonly used in immunotherapy and originally for non-small-cell lung carcinoma (NSCLC). It binds to the program...
PD-1/PD-L1 Inhibitor 1
PD-1/PD-L1 Inhibitor 1, is an inhibitor of the PD-1 /PD-Ll protein/protein interaction.
A human immunoglobulin G1 (IgG1) monoclonal antibody binds to PD-L1 and prevents the interaction of PD-L1 with its receptor PD-1, with potential immune checkpoi...
A human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibi...